Cell Bio Human Tech Co., Ltd

Cell Bio Human Tech Co., Ltd

KKRX:318160
5,050.00
KRW
-410.00
(-7.51%)
1,202.60EPS
4.72P/E
49.00BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,525,428.69
3,430.51
2,669.91
3,598.14
4,525.11
3,936.45
3,236.95
3,186.67
6,201
7,144.87
Basic EPS, GAAP
423,511.02
1,121
499
527
403
413
-220
491
1,059
1,239.59
Free Cash Flow per Basic Share
144,208.81
327.05
343.83
-1,198.97
484.47
8.98
74.22
812.37
-646.24
-812.81
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,592.61
2,904.01
6,713.65
6,234.01
4,059.42
4,527.97
4,765.58
5,383.59
6,721.25
7,277.24
Tangible Book Value per Share
1,591.15
2,893.62
6,610.55
6,099.05
3,942.62
4,411.09
4,627.08
5,236.55
6,548.53
7,048.81
Basic Weighted Avg Shares
- -
8
9
8
8
7
8
9
8
9
Sales/Revenue/Turnover
18,583
27,570
24,103
28,588
35,161
27,545
27,324
28,419
51,066
60,901
Operating Margin (%)
31.1
36.56
19.69
18.51
15.96
12.83
11.53
14.2
18.25
16.05
Depreciation Expense
308
356
982
1,151
1,539
1,861
1,803
1,906
2,434
3,028
Net Income, GAAP
5,159
9,009
4,505
4,187
3,131
2,890
-1,857
4,379
8,721
10,566
Effective Tax Rate (%)
12.02
10.37
10.21
11.97
30.51
18.38
- -
15.65
3.21
4.35
Profit Margin (%)
27.76
32.68
18.69
14.65
8.91
10.49
-6.8
15.41
17.08
17.35
Working Capital
5,997
14,090
35,014
20,221
12,594
6,230
18,359
17,709
24,823
27,317
LT Debt
- -
- -
97
459
275
69
22
175
9,190
12,724
Total Equity
11,139
20,331
47,542
44,213
28,867
32,147
44,563
46,412
59,003
63,581
Return on Invested Capital (%)
- -
54.4
12.26
9.96
9.71
7.92
- -
6.7
13.79
13.72
Return on Capital (%)
- -
57.26
13.44
8.99
9.05
9.12
- -
9.36
13.93
17.04
Return on Common Equity (%)
- -
57.24
13.38
9.24
8.69
9.61
-4.9
9.72
17.06
19.68

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11,320
11,823
8,256
LT Borrowings
8,907
8,955
12,421
LT Finance Leases
283
274
303
Preferred Equity and Hybrid Capital
447
447
447
Shares Outstanding
8
8
8
Market Capitalization
68,430
58,630
48,998

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
44,021
45,929
41,953
Cash, Cash Equivalents & STI
16,601
19,036
11,912
Accounts Receivable, Net
10,856
9,924
13,270
Inventories
13,858
15,092
14,939
Total Current Liabilities
19,197
18,882
14,636
Payables & Accruals
- -
- -
- -
ST Debt
11,320
11,823
8,256
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.31%
27.13%
Free Cash Flow
- -
308.35%
-173.46%
Net Income, GAAP
- -
-86.76%
99.17%
Sales/Revenue/Turnover
- -
16.85%
79.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,956
7,130
7,082
8,251
28,419
2025
8,288
13,988
14,539
14,251
51,066
2026
12,747
19,363
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70
90
104
229.33
491
2025
163
178
383.47
269.35
1,059
2026
227.71
351
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kwon-Sun Lee
Full Time Employees
97
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Anyang-si South Korea
IPO Date
Apr 20, 2023
Business
Cell Bio Human Tech Co., Ltd. is a South Korea-based biomaterials and cosmetics manufacturing company specializing in the development, production, and supply of high-performance cellulose nonwoven fabrics, functional skincare sheets, and cosmetic original development manufacturing (ODM) and original equipment manufacturing (OEM) solutions. Founded in July 2015 and headquartered in Anyang-si, Gyeonggi-do, South Korea, the company operates across the personal care, functional skincare, and bio-medical healthcare sectors. The company's core business is organized into functional bio-materials, cosmetic finished goods manufacturing, and specialized healthcare patches. Its product and service portfolio comprises: proprietary cellulose nonwoven fabrics for facial sheet masks, including PT CELL (Premium Transparent Cell) bio-cellulose sheets characterized by high essence absorption and skin adhesion; SEMI GEL functional fabrics that convert into a gel structure upon moisture absorption; NF CELL, S CELL, and S BR customized functional fabric lines; cosmetic ODM and OEM services providing end-to-end skincare development, formulation, and packaging for sheet masks, toner pads, essence treatments, and nose strips; hydrocolloid-based personal care items, including acne spot patches, soothing facial blemish patches, and pore care pads; medical-grade wound care materials, including hydrocolloid wound dressings and protective skin barriers; and proprietary clean beauty skincare lines under brand names such as Lusom. The company caters to domestic and global cosmetics brand owners, contract manufacturers, and beauty distributors across key markets, including South Korea, China, Japan, the United States, and Europe. Cell Bio Human Tech Co., Ltd. maintains corporate headquarters and manufacturing facilities in Anyang-si and Hwaseong-si, South Korea, and supports global distribution through its overseas manufacturing subsidiary, Staami Vina Co., Ltd. (Cellbiohumantech Vina), located in Vietnam. In recent corporate developments, the company listed its shares on the KOSDAQ market (Ticker: KRX:318160) through a merger with Daishin Balance No. 12 SPAC. To enhance its functional skincare offerings and research capabilities, the company formed a strategic partnership with Kolmar Korea Co., Ltd. to co-develop eco-friendly and high-functional cosmetic fiber materials. Furthermore, the company has expanded production processes at its Vietnam manufacturing facility to enhance cost efficiencies and scale global supply capacity, while executing a strategic business diversification from raw sheet mask materials into full-service finished skincare ODM, transdermal hydrocolloid patches, and medical wound dressings.